Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876724 | 0.99 | KMT2A (0.43) | ALDH1A1KMT2AMEN1KDM4ESIGMAR1 | |
| SCHEMBL4179654 | 0.78 | BCHE (0.38) | KMT2AMEN1SIGMAR1 | |
| SCHEMBL3217075 | 0.77 | BCHE (0.37) | SIGMAR1 | |
| SCHEMBL3205175 | 0.77 | BCHE (0.37) | SIGMAR1 | |
| SCHEMBL4884661 | 0.77 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL4193590 | 0.76 | DRD2 (0.39) | ALDH1A1KMT2AMEN1KDM4EMCHR1 | |
| SCHEMBL4887368 | 0.76 | CHRM2 (0.33) | — | |
| SCHEMBL4889431 | 0.72 | CHRM3 (0.51) | ALDH1A1KMT2AMEN1KDM4ESIGMAR1 | |
| SCHEMBL4885818 | 0.72 | NAAA (0.36) | ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL4876714 | 0.72 | CHRM3 (0.51) | ALDH1A1KMT2AMEN1SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 1047/4885KMT2A 3710/4885MEN1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.